SEARCH
Tynax ~ Patent Library

Patent for License:

Bioimplant    

A titanium based composite bioactive (biocompatible) material useful as prosthetic implant as against conventional processes

Overview

The technology is aimed at addressing the various shortcomings associated with the existing implants thereby improving implant making processes. The technology provides titanium based composite bioactive (biocompatible) material useful as prosthetic implant as against conventional processes where-in the bioactive phases, usually calcium phosphatic chemicals, is present on the surface of the bioinert Ti. The titanium based implant allows tissue growth deep into the composite as against the conventional Ti based surface-coated implants which enable only surface integration because of the presence of bioactive phase only on the surface allowing tissue growth only at the surface of the implant, limited to the thickness of the bioactive coated phase. The implant when implanted in place of a damaged bone, can locate itself securely at the implantation and enables through integration with the healthy bone, thus completely avoiding any possibility of the implant getting loosened. The Ti based biocompatible material is capable of extracting out biological HA from the body fluids hence it substitutes the need of synthetic HA. Titanium oxide and certain calcium phosphatic and chemicals, which get formed in the present invention, have the potential to precipitate out biological HA from body fluids. This fact is proved by immersing the implant in SBF (Simulated Body Fluids). In biological HA the sizes of individual particles are more uniform. In the context of longevity of the implant, it is better to have more amount of biological HA in the implant and reduce the amount of synthetic HA.

Primary Application of the Technology

Prosthetic devices for treatment of bone injuries / illnesses.

The Problem Solved by the Technology

A number of coating processes have been used to coat implants with different kind of materials. Some inherent disadvantages associated:

- Implant become loose over the period of time, result into implant failure; Not fit for younger and more physically active patients.

- Minimum pore size for load-bearing implants and porous coatings require different technologies.

- Fast dissolution of the amorphous phase and some of the crystalline products like tricalcium phosphate degrade the stability of the coating, not suitable for coating implants that have complex shapes.

How the Technology Solves the Problem

Fast dissolution of the amorphous phase and some of the crystalline products like tricalcium phosphate degrade the stability of the coating, not suitable for coating implants that have complex shapes.

Competitive Advantage

The bioactive phases are not directly added to Ti, but added in the form of salts of calcium and phosphorus which during processing, convert into different bioactive phases within the bio inert Ti in situ - thereby ensuring proximity of the bioactive phases thus formed with the Ti phase. In vitro-cytotoxicity tests were performed and it was confirmed that the biocomposite produced by the process of this technology is non-cytotoxic.

Comments on Deal Structure, Potential Terms and Restrictions

Available for licensing; Buyer-side commission fee